A randomized phase II study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer

BACKGROUND: Use of radiopharmaceutical may improve the survival time of patients with castrate-resistant prostate cancer and bone metastases. Whether androgen-deprivation therapy (ADT) combined with bone-targeted therapy provides clinical benefit for patients with advanced castrate-sensitive prostat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Bilen, Mehmet Asim, Johnson, Marcella M., Mathew, Paul, Pagliaro, Lance C., Araujo, John C., Aparicio, Ana, Corn, Paul G., Tannir, Nizar M., Wong, Franklin C., Fisch, Michael J., Logothetis, Christopher, Tu, Shi-Ming
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4270821/
https://ncbi.nlm.nih.gov/pubmed/25155428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28971
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars